Niagen Bioscience, Inc. NAGE
Nasdaq · stock · Medicinal Chemicals & Botanical Products · website · IPO 2007-06-25
Niagen Bioscience, Inc. statistics & valuation
Market cap$272.4M
P / E15.7×
P / S2.1×
P / B3.6×
Net margin13.4%
Return on equity22.7%
Return on capital18.8%
Graham number -34.4%$2.01
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($2.01); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 64.3% | 61.8% | 60.8% | 59.4% | 61.5% | 59.5% | 55.7% | 50.9% | 49.4% | — |
| Operating margin | 12.6% | 7.8% | -6.7% | -25.9% | -40.1% | -33.5% | -67.6% | -105.1% | -77.2% | — |
| Net margin | 13.4% | 8.6% | -5.9% | -23.0% | -40.2% | -33.6% | -69.4% | -105.6% | -53.7% | — |
| FCF margin | — | — | — | — | — | — | -45.8% | -70.4% | -51.7% | — |
| Return on assets | 16.3% | 12.5% | -9.0% | -30.6% | -46.9% | -51.9% | -79.9% | -78.9% | -18.1% | -14.8% |
| Return on equity | 22.7% | 18.5% | -17.4% | -57.7% | -85.5% | -121.3% | -157.2% | -122.6% | -21.1% | -29.4% |
| Debt / equity | — | — | — | — | — | — | — | — | — | 0.00× |
| Current ratio | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 | 1.96 | 2.23 | 2.53 | 7.07 | 1.77 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.